StockTwits, founded in 2008 by Howard Lindzon and Soren Macbeth, is a leading social media platform designed specifically for investors and traders to share real-time market insights, ideas, and strategies. Headquartered in New York City, the company pioneered the use of "cashtags" (e.g., $AAPL) to organize financial discussions, initially integrating with Twitter before evolving into a standalone network.
The deal, pending regulatory approval, will add NeuraFlash’s specialized team of approximately 510 professionals, who hold more than 2,000 Salesforce certifications, to Accenture’s Salesforce Business Group.
According to the Wall Street Journal, citing an internal memo, Whole Foods’ employees, mainly in the roles of marketing and merchandising, will have a month to review and evaluate their new titles, salaries, and benefits.
The U.S. auto safety regulator said that an instrument panel display that does not show critical information, such as warning lights or vehicle speed, can increase the risk of a crash.
If Brent prices hover around $50, many oil producers might struggle to provide the attractive capital returns that have pulled some investors back to the sector.
Xpeng’s five-year American journey has been marked by soaring IPO highs, sharp corrections, and steady delivery growth that’s kept it in the race with Nio and Li Auto, even as Tesla’s scale continues to tower over the sector.
With Cook resisting the move, the immediate onus is on Fed Chair Jerome Powell, as he has the obligation and right to ask the Trump administration, “Show me the legal basis for this action,” Krugman said.
Craig-Hallum analyst Eric Stine noted that the expansion of the partnership between KHNP and Centrus underscores the latter firm’s geopolitical significance
Analysts at Bernstein called the survival data “a positive surprise,” framing it as Akeso’s biggest catalyst since the drug previously outperformed Merck’s top-selling cancer therapy.
The after-hours surge came as management pointed to hospital market share gains from a distracted competitor and rising bronchiectasis awareness following Insmed’s FDA-approved drug launch.
The company reported second-quarter adjusted earnings per share of $1, reversing from an adjusted loss of $0.70 per share in the year-ago quarter, and 24% YoY revenue growth.
